NCT04924413 2024-07-03L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant MelanomaHenan Cancer HospitalPhase 2 Terminated9 enrolled
NCT03166397 2023-01-26Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma PatientsSheba Medical CenterPhase 2 Recruiting30 enrolled
NCT03383237 2017-12-27Clinical Study of Apatinib as the Second-line Therapy in Malignant MelanomaHenan Cancer HospitalPhase 2 Unknown20 enrolled
NCT00287131 2012-03-29Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma PatientsSheba Medical CenterPhase 2 Unknown70 enrolled